High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models.

ABSTRACT: Recent advances in the ability to efficiently characterize tumor genomes is enabling targeted drug development, which requires rigorous biomarker-based patient selection to increase effectiveness. Consequently, representative DNA biomarkers become equally important in pre-clinical studies. However, it is still unclear how well these markers are maintained between the primary tumor and the patient-derived tumor models. Here, we report the comprehensive identification of somatic coding mutations and copy number aberrations in four glioblastoma (GBM) primary tumors and their matched pre-clinical models: serum-free neurospheres, adherent cell cultures, and mouse xenografts. We developed innovative methods to improve the data quality and allow a strict comparison of matched tumor samples. Our a

SUBMITTER: Yost SE 

PROVIDER: S-EPMC3575368 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature